Table 1.

Baseline patient and disease characteristics.

		All patients n = 135	Randomised patients after ASCT
			No further treatment n = 30	Bortezomib maintenance n = 30
Age (median; range)		57 (34–66)	54 (36–65)	56 (34–66)
Male sex		78%	77%	80%
WHO performance
WHO 0		105 (78%)	25 (83%)	25 (83%)
WHO 1		60 (19%)	5 (17%)	4 (13%)
WHO 2		5 (4%)		1 (3%)
Ann Arbor stage
II		11 (8%)	1 (3%)	3 (10%)
III		8 (6%)	2 (7%)	2 (7%)
IV		116 (86%)	27 (90%)	25 (83%)
MIPI score
Low		77 (57%)	21 (70%)	15 (50%)
Intermediate		43 (32%)	6 (20%)	11 (37%)
High		13 (10%)	3 (10%)	3 (10%)
Unknown		2 (1%)		1 (3%)
Bone marrow involvement		112 (83%)	26 (87%)	24 (80%)
MIB1	<30%	62 (46%)	11 (37%)	17 (57%)
	≥30%	25 (18%)	8 (26%)	5 (17%)
	unknown	48 (36%)	11 (37%)	8 (26%)
P53	<50%	68 (50%)	17 (57%)	18 (60%)
	≥50%	7 (5%)	1 (3%)	0 (0%)
	unknown	60 (45%)	12 (40%)	12 (40%)